Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
Deals
|
July 26 2007
Isotechnika partner receives no objection letter from Health Canada Isotechnika Inc. announces its partner, Lux Biosciences, has received a No Objection Letter from Health Canada to investigate ISA247 (referred to as LX211 by Lux) in Phase II/III clinical trials for the treatment of uveitis.
|
|
July 26 2007
Dealmakers Resverlogix Corp. (Calgary, AB) closes bought deal private placement providing for the sale and issuance of US$25 million in aggregate principal amount of secured convertible promissory notes.
|
|
July 26 2007
Maker of COLD-fX appoints chief operating officer CV Technologies Inc., the makers of the popular cold and flu remedy COLD-fX(R), appoints Ross Montagano as its new chief operating officer (COO).
|
|
July 26 2007
MediSolution undergoes facelift Leading healthcare and service sector IT company MediSolution has formally unveiled its new brand identity and renamed its MPlex Solutions public and service sector division to Virtuo Solutions effective immediately.
|
|
July 26 2007
MaRS Landing expands its team MaRS Landing announces the addition of Barbara Dillingham its project manager as well as the appointment of Michelle Schurter as the company's director of government and corporate affairs.
|
|
July 26 2007
Sigma-Aldrich acquires Molecular Medicine BioServices Sigma-Aldrich Corporation announces it has acquired Molecular Medicine BioServices Inc. (MMB), a biopharmaceutical contract manufacturing organization (CMO) to further enhance the biologics capabilities within its SAFC Pharma business segment.
|
|
July 26 2007
Vasogen closes previously announced financing Vasogen Inc. announces the closing of its previously announced financing for US$16 million in gross proceeds through the sale of its common shares at a price of US$3.25 under the terms of the purchase agreements.
|
|
July 26 2007
Joseph Beckman joins Amorfix Amorfix Life Sciences, a company focused on diagnostics and treatments for brain wasting diseases, announces the appointment of Dr. Joseph Beckman to its scientific advisory board.
|
|
July 26 2007
Amorfix achieves first milestone in therapeutic ALS partnership with Biogen Idec Amorfix Life Sciences receives notice from Biogen Idec that it will be exercising the first milestone investment under the August 2006 research and investment agreement. The milestone investment allows Biogen Idec to retain its exclusive worldwide option to license Amorfix's therapeutic candidates for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease.
|
|
July 25 2007
Clinical Trials & Patents Liponex Inc. (Ottawa, ON) reports further analysis of its CRD5 Phase I/II clinical trial has shown its lead product to be safe in dyslipidemic patients.
|
|
July 13 2007
Pall teams up with RITT to advance transplantation science Pall Corporation announces the establishment of a collaborative sponsorship agreement with the Research in Immune Tolerance in Transplantation (RITT) program at the Toronto General Hospital (University Health Network) located in Toronto.
|
|
July 13 2007
Canadian, British and American scientists launch genome partnership An international team will use state-of-the-art, high-density microarrays and new computer algorithms to improve the detection of variants in the human genome, which are implicated in various diseases.
|
|
July 13 2007
Canadian Cardiovascular Society, mdBriefCase and AdvancingIn team up to provide online resources The Canadian Cardiovascular Society (CCS), AdvancingIn and mdBriefCase Inc. form a new partnership to provide on-line support for Canadian cardiovascular healthcare professionals. Advancing In Cardiovascular Health will provide CCS members and healthcare professionals with an interest in cardiovascular medicine with access to free, convenient, interactive continuing educational programming resources, including CME programs, eSymposia and national discussion forums.
|
|
July 13 2007
Med BioGene closes second and final tranche of private placement Med BioGene Inc. closes the second and final tranche of its previously announced private placement. MBI issued an aggregate of 677,500 units at a price of $0.45 per unit for aggregate gross proceeds of approximately $305,000.
|
|
July 13 2007
CV Technologies confirms trading to resume; updates new corporate priorities CV Technologies Inc. confirms that Securities Commissions in Alberta, Ontario and British Columbia have lifted their Cease Trade Orders, clearing the way for the Toronto Stock Exchange to lift the trading halt on CVQ stock.
|
|
July 13 2007
Warnex engages GMP Securities L.P. as advisor Warnex Inc. engages GMP Securities L.P., an institutional investment dealer with locations across Canada, to act as advisor in its previously announced review of strategic options.
|
|
July 10 2007
PerkinElmer and Axxam to deliver advanced screening solutions PerkinElmer, Inc. signs a worldwide licensing agreement with Axxam SpA, a Milan, Italy-based company focused on early-stage discovery research and services for the life science industry, to become the exclusive provider of Axxam's Photina(R) photoprotein technology to the drug discovery market.
|
|
July 10 2007
Kendle selects ClinPhone EDC as preferred solution ClinPhone signs an agreement to utilize ClinPhone EDC to standardize its method of capturing clinical data for its biopharmaceutical customers worldwide.
|
|
July 05 2007
GE Healthcare and Abbotsford Regional Hospital and Cancer Centre sign $30 million agreement GE Healthcare will provide more than $30 million in equipment and services to the Abbotsford Regional Hospital and Cancer Centre, scheduled to open for patients in summer 2008. GE Healthcare was uniquely positioned to help identify the various needs of the hospital and meet them with equipment that is among the most innovative and technologically advanced on the market.
|
|
July 03 2007
Warnex signs agreement with Clinique Radiologique Quatre-Bourgeois to offer Prenatest(R) screening in Quebec City Warnex Inc. announces that it has signed an agreement with Clinique radiologique Quatre-Bourgeois to provide the Prenatest(R) prenatal screening test in Quebec City.
|
|
July 03 2007
Abbott and Caprion extend partnership to discover antibody targets for cancer Abbott and Caprion Proteomics extend its discovery partnership to investigate viable human therapeutic antibody targets for oncology using its CellCarta(R) technology platform. The two companies began working together on lung cancer targets three years ago.
|
|
July 03 2007
Neurochem announces it has obtained written consent from its shareholders Neurochem Inc. announces that, in connection with its previously announced private placement of US$80 million aggregate principal amount of convertible notes and warrants to purchase common shares, it has provided the Toronto Stock Exchange with written evidence that holders of more than 50% of its securities are familiar with the terms of the Notes and Warrants and are in favour thereof.
|
|
June 25 2007
Stem Cell Therapeutics Corp. announces financial results Stem Cell Therapeutics Corp. (SCT) announces its financial results for the period ended Dec. 31, 2006.
|
|
June 25 2007
NeuroScience Canada appoints directors Allan R. Taylor, interim chair of the board of directors of NeuroScience Canada announces the appointments of three directors.
|
|
June 25 2007
Dealmakers Saskatchewan Wheat Pool Inc. (Regina, SK) announces that the $275,400,000 subscription receipt offering has closed successfully and that Genuity Capital Markets, TD Securities Inc. and National Bank Financial Inc., that acted as underwriters in connection with the offering, have exercised its over-allotment option in full to purchase an additional 5,100,000 subscription receipts at the offering price of $8.10 per subscription receipt, bringing aggregate proceeds of the offering to $316,710,000.
|
|
June 25 2007
Protox reports 2006 achievements and financial results Protox(TM) Therapeutics Inc. announces its year-end financial statements for the 12 months ending Dec. 31, 2006, revealing not only its financial status but its achievements during the year.
|
|
June 25 2007
Pfizer Canada receives IAPA Health and Safety award IAPA (Industrial Accident Prevention Association) recognizes the workplace health and safety accomplishments of Pfizer Canada's Arnprior facility with a Level I Health & Safety Achievement Award.
|
|
June 25 2007
ARIUS makes changes to board of directors Arius Research Inc. announces that Joseph Zakrzewski has been appointed to the company's board of directors.
|
|
June 25 2007
Biophage Pharma appoints new chief financial officer Biophage Pharma Inc. announces the appointment of Louis Guindon as chief financial officer and treasurer of the corporation.
|
|
June 22 2007
BD Biosciences and StemCell Technologies sign license agreements with WARF BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc., a Vancouver-based life sciences company, announce they have entered into a worldwide license agreement with the Wisconsin Alumni Research Foundation (WARF).
|
|
June 18 2007
Health Canada allows Isotechnika to continue patients on ISA247 until commercialization Isotechnika announces that the company has received a No Objection Letter from Health Canada for the long term use of ISA247 in patients currently participating in the Canadian arm of the company's Phase 2b kidney transplant trial.
|
|
June 18 2007
Nuvo continues discussions with the FDA related to Pennsaid Nuvo Research Inc. is continuing discussions with the U.S. Food and Drug Administration to clarify and resolve matters raised by the FDA in its approvable letter for Pennsaid issued in December 2006. The discussions primarily concern the FDA's requirements for data to evidence the dermal safety of Pennsaid and its constituent components.
|
|
June 18 2007
GangaGen, University of Nottingham sign research agreement GangaGen Life Sciences Inc. and the University of Nottingham are engaging in a major research project to develop a bacteriophage-based treatment for the control of Campylobacter bacteria in poultry. Along with Salmonella, Campylobacter is the most common form of food-borne illness, infecting millions of people worldwide every year.
|
|
June 06 2007
Lawson Health Research Institute Announces Appointment Lawson Health Research Institute (London, ON) announces that it has appointed Dr. David Hill to the position of scientific director for the Institute.
|
|
June 06 2007
Neptune Technologies and Bioressources announce recent appointment Neptune Technologies and Bioressources announce that Thierry Houillon, recently appointed member of Neptune's board of directors and previous CEO of Danone Canada, has joined Neptune as the vice president, Business Development, Functional Food.
|
|
June 06 2007
Universal Measurement Solutions Ltd. has New VP of sales and marketing Universal Measurement Solutions Ltd. leverages its rapidly growing market presence with the addition of R.A. (Bob) Ell as VP of sales and marketing.
|
|
June 06 2007
Cipher announces new CFO appointment Cipher Pharmaceuticals Inc. announces that Norman C. Evans, CA, has been appointed chief financial officer of the company, effective immediately.
|
|
June 06 2007
Cytochroma Inc. announces new appointment Cytochroma Inc. announces the appointment of Dr. P. Martin Petkovich as full-time chief scientific officer.
|
|
June 06 2007
Aegera Therapeutics Inc. announces appointments Aegera Therapeutics Inc. announces the appointment of James M. Rae as chairman of the board and Trudie Resch as board director.
|
|
June 04 2007
AEterna terminates its license agreement with Solvay Pharmaceuticals Quebec biotech company AEterna Zentaris has regained exclusive worldwide rights for its lead Luteinizing Hormone-Releasing Hormone (LHRH) antagonist, Cetrorelix, after terminating its License and Cooperation Agreement in all remaining indications, including endometriosis, with its partner Solvay Pharmaceuticals.
|
|
June 04 2007
Beckman Coulter Selects SAFC Supply Solutions as Licensing Partner Beckman Coulter, a manufacturer and distributor of biomedical testing instrument systems and research products, has chosen SAFC Supply Solutions business segment as a licensing partner for its fast deprotection chemistry technology.
|
|
June 04 2007
Allon Therapeutics closes $15 million bought financing deal Allon Therapeutics Inc. announces it has entered into a bought deal financing agreement with a syndicate of Canadian securities dealers under which the syndicate has agreed to purchase 12,500,000 units at a price of $1.20 per Unit, resulting in gross proceeds of $15 million.
|
|
June 04 2007
Advitech closes private placement deal with AgeChem Advitech Inc. announces the closing of a $970,000 private placement with AgeChem Venture Fund L.P. and new payment terms of its convertible debentures issued in 2004.
|
|
June 01 2007
New partnership leverages promising Canadian stem cell IP MaRS Discovery District and the Canadian Stem Cell Network (SCN) announce a partnership agreement whereby MaRS and SCN will work together to pursue long-term public or private financing for the translational development activities currently being undertaken by Aggregate Therapeutics Inc.
|
|
June 01 2007
ART Advanced Research Technologies Inc. closes a first portion of private placement ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces that it has closed a first portion of approximately $4.5 million of its previously announced private placement of a total of approximately $5.5 million.
|
|
June 01 2007
Thermo Fisher Scientific appoints new director to Canadian team Murray Wigmore has been promoted to the director, Canada Commercial Sales and North America Consumables for the Scientific Instruments Division of the Advanced Products Group for Thermo Fisher Scientific.
|
|
May 24 2007
Ambrilia announces closing of $5.8 million private placement Ambrilia Biopharma Inc., a biopharmaceutical company specializing in the development of novel small molecules and peptides to treat infectious diseases and cancer, announces the closing of a $5.8 million private place.
|
|
May 22 2007
CCR Technologies Ltd. completes private placement CCR Technologies Ltd. announces that on April 16, 2007 the corporation completed a private placement of a series of secured convertible debentures in the aggregate principal amount of $500,000, which mature on Dec. 19, 2009.
|
|
May 17 2007
York University and Japanese biomedical foundation confirm partnership York University and Japan's Foundation for Biomedical Research and Innovation have formalized a memorandum of understanding to promote the development and commercialization of innovative medical devices used to diagnose, treat and even prevent illnesses.
|
|
May 16 2007
Cytochroma's new chief scientific officer to propel development and commercialization Cytochroma Inc. announces the appointment of Dr. P. Martin Petkovich as full-time chief scientific officer
|